CYTOKINETICS EVP sells 7,449 CYTK shares

CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock.

Rhea-AI Filing Summary

CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock. As EVP and Chief Commercial Officer, he sold 7,449 shares of Common Stock at a price of $66.02 per share. Following this transaction, he directly holds 58,555 shares of CYTOKINETICS INC Common Stock.

Insights

Insider trading and governance analyst

Routine-sized open-market sale by a senior executive, with substantial holdings retained.

EVP and Chief Commercial Officer Andrew Callos executed an open-market sale of 7,449 shares of CYTOKINETICS INC Common Stock at $66.02 per share. The transaction is coded as an open-market sale, which is a discretionary move rather than a mechanical event like tax withholding.

After the sale, Callos still directly owns 58,555 shares, indicating he retains a significant equity position. The filing shows no derivative positions and no footnote disclosures about trading plans or indirect ownership in this excerpt. Based on the available data, this appears to be a routine insider sale rather than a transformative event.

Insider Trade Summary 10b5-1

Net Seller: 7,449 shares

Net Sell 1 txn

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 7,449 shs ($492K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,449	$66.02	$492K

Holdings After Transaction: Common Stock — 58,555 shares (Direct)

Key Figures

Shares sold: 7,449 shares Sale price: $66.02 per share Shares held after transaction: 58,555 shares

3 metrics

Shares sold 7,449 shares Open-market sale of CYTOKINETICS INC Common Stock

Sale price $66.02 per share Price for the 7,449 shares sold

Shares held after transaction 58,555 shares Direct ownership by Andrew Callos following the sale

Key Terms

open-market sale, Common Stock, transaction code "S", direct ownership, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code "S" financial

"transaction_code_description: "Sale in open market or private transaction""

direct ownership financial

"ownership_type: "direct""

net-sell financial

"netBuySellDirection: "net-sell""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK executive Andrew Callos report?

Andrew Callos reported an open-market sale of CYTOKINETICS INC (CYTK) Common Stock. He sold 7,449 shares at $66.02 per share, and the transaction was classified as a non-derivative, open-market sale under transaction code "S" in a Form 4 filing.

How many CYTK shares does Andrew Callos hold after this Form 4 sale?

After the reported sale, Andrew Callos directly holds 58,555 shares of CYTOKINETICS INC (CYTK) Common Stock. This post-transaction balance reflects his remaining direct ownership following the open-market sale of 7,449 shares disclosed in the Form 4.

At what price did Andrew Callos sell his CYTK shares in this filing?

Andrew Callos sold his CYTOKINETICS INC (CYTK) Common Stock at $66.02 per share. The Form 4 indicates an open-market transaction involving 7,449 shares of Common Stock at that price, classified under transaction code "S" for a sale in the open market.

What role does Andrew Callos hold at CYTOKINETICS INC (CYTK)?

Andrew Callos serves as Executive Vice President and Chief Commercial Officer at CYTOKINETICS INC (CYTK). His officer status is disclosed in the Form 4, where he reports a sale of 7,449 shares of Common Stock in an open-market transaction while retaining 58,555 shares afterward.

Was the CYTK insider transaction by Andrew Callos a buy or sell?

The transaction reported by Andrew Callos was a sell. The Form 4 classifies it as an open-market sale under transaction code "S," with 7,449 shares of CYTOKINETICS INC (CYTK) Common Stock sold at $66.02 per share, reducing but not eliminating his direct holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		S		7,449	D	$66.02	58,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)